Product Reports Resources Pricing Login Book a demo

Freenome

Biotech & Life Sciences · San Francisco, United States · Founded 2014 · Public via SPAC 2026

A health technology company developing accurate, accessible and non-invasive disease screening products

Valuation $1.28B
Revenue $30M

Investors

48 investors on Freenome's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 5 investors entered at this stage
Founders Fund
DCVC
Third Kind Venture Capital
Andreessen Horowitz
Loxbridge Research
Series A 9 investors entered at this stage
Series B+ 34 investors entered at this stage
Kaiser Permanente Ventures
EcoR1 Capital
T. Rowe Price
Quest Diagnostics
Logos Capital
Squarepoint Capital
Farallon Capital Management
Kaiser Permanente
Roche
ARK Invest
Roche Venture Fund
RA Capital Management
BrightEdge
Fidelity Investments
HBM Healthcare Investments
Rock Springs Capital
Pura Vida Investments
Eventide Asset Management
Sands Capital Management
Cormorant Capital
The Colon Cancer Alliance
Novartis
Cormorant Asset Management
ArrowMark Partners
Perceptive Advisors
Artis Ventures
Ridgeback Capital
Intermountain Ventures
Bain Capital Life Sciences
Suvretta Capital Management
Catalio Capital Management
Janus Henderson Investors
Byers Capital
Soleus Capital

Ownership

Who owns Freenome

Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (2026).

32.5% Roche

See the full cap table on Dealroom →

Global footprint

Where Freenome has talent and traffic

Workforce by country
8 countries with
team presence
🇺🇸 United States96.2%
🇬🇧 United Kingdom1%
🇨🇦 Canada0.6%
🇨🇭 Switzerland0.6%
🇦🇹 Austria0.6%
Top 5 of 8 shown
Web traffic by country
20K monthly visits
across markets
🇺🇸 United States92.5%
🇬🇧 United Kingdom3.5%
🇮🇳 India2.5%
🇵🇭 Philippines0.5%
🇩🇪 Germany0.5%
Top 5 markets shown

Talent graph

The shape of Freenome's talent

Dealroom maps Freenome's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

15 standout operatorsDealroom-flagged across the org
14 AI specialistsincl. 9 core researchers
403 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Freenome's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$7M patent portfolio · 21 active families

Estimated portfolio value
$7M
0.58% of market cap · 5.4× smaller than top peer Caris Life Sciences ($40M)
21 active patent families
Where Freenome innovates Anticentromere antibodiesAutoantibody productionBioinformaticsCancer researchCell

Where Freenome concentrates vs peers

Each axis is a top-10 topic across Freenome and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Freenome

An AI-synthesized read of the highest-engagement posts about Freenome on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Freenome on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.